Oral Docetaxel in Patients With Normal or Impaired Liver Function
Status:
Withdrawn
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
This is an open label, single centre pharmacological and safety study to define the safety
and pharmacokinetics of ModraDoc006/r in a weekly dosing schedule in patients with impaired
liver function who might have benefit from a weekly docetaxel regime. The safety of
ModraDoc006 in combination with ritonavir for the patients with mild and moderate impaired
liver function will be evaluated with a dose escalation design.